Innovent Biologics, Inc. (IVBXF)
| Market Cap | 19.90B +202.2% |
| Revenue (ttm) | 1.59B +53.2% |
| Net Income | 158.06M |
| EPS | 0.09 |
| Shares Out | n/a |
| PE Ratio | 125.89 |
| Forward PE | 54.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 17,031 |
| Open | 11.45 |
| Previous Close | 11.36 |
| Day's Range | 11.45 - 11.45 |
| 52-Week Range | 4.64 - 15.12 |
| Beta | 0.23 |
| RSI | 55.24 |
| Earnings Date | Mar 26, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec... [Read more]
Financial Performance
In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Hong Kong stocks extend bounce-back from tech turbulence as risk sentiment returns
Hong Kong stocks gained, extending a rebound from a sell-off in technology companies, as traders returned to the risk-on mode on bets that the tumult has run its course. The Hang Seng Index rose 0.9 p...
Innovent Biologics Strikes Partnership Deal With Eli Lilly
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
China's Innovent clinches new Lilly deal for immunology, cancer drug development
China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and as much as $8.5 billion more ...
Hong Kong stocks start week strong on sentiment stabilisation, Japan election
Hong Kong stocks rose alongside other markets in Asia, as sentiment towards global risk assets stabilised and the victory of Japan’s ruling party in the parliamentary election boosted risk appetite. T...
Innovent And Lilly Expand Collaboration To Advance Global Oncology & Immunology Drugs
(RTTNews) - Innovent Biologics Inc. (IVBXF, 1801.HK) announced a new strategic collaboration with Eli Lilly and Company. This marks the seventh partnership between the two companies, further strengthe...
Innovent Biologics (IVBIY) Expands Partnership with Eli Lilly for Cancer Drug Development
Innovent Biologics (IVBIY) Expands Partnership with Eli Lilly for Cancer Drug Development
Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializ...
Innovent Biologics Receives FDA Fast Track Designation For IBI3003 In R/R Multiple Myeloma
(RTTNews) - Innovent Biologics Inc. (IVBXF, 1801.HK) announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Adm...
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China , Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializ...
Innovent Biologics: TABOSUN Receives NMPA Approval
(RTTNews) - Innovent Biologics (IVBXF, 1801.HK) announced that the New Drug Application for TABOSUN has been approved by China's National Medical Products Administration, in combination with sintilima...
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instabili...
Innovent's Mazdutide Shows Significant Weight Loss & Metabolic Benefits In Chinese Adolescents
(RTTNews) - Innovent Biologics Inc. (IVBXF, 1801.HK) announced that its Phase 1b clinical trial of mazdutide injection (IBI362), a GLP-1 and glucagon dual receptor agonist, in Chinese adolescents with...
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Innovent's PECONDLE Delivers Durable Efficacy And Safety In Phase 3 Psoriasis Trial
(RTTNews) - Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that PECONDLE (picankibart injection), its self-developed recombinant anti-interleukin-23p19 subunit ...
ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China , Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China , Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies
(RTTNews) - Innovent Biologics (IVBXF, 1801.HK) announced that its global strategic collaboration with Takeda (4502.T, TAK) has officially closed and become effective following the satisfaction of all...
China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
PECONDLE® (picankibart injection) has received approval from China's National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are ...
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value
SAN FRANCISCO and SUZHOU, China , Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-q...
Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index
Innovent Biologics will join the Hang Seng Index next month in the latest quarterly review as the compiler of the city’s stock benchmark presses ahead with its plan to increase the number of constitue...
Innovent Biologics' Mazdutide Phase 3 Trial In Obesity Achieves Primary & Key Secondary Endpoints
(RTTNews) - Innovent Biologics, Inc. (IVBXF, 1801.HK) announced that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in ...